应用超声心动图评估肝硬化患者心脏结构和功能临床价值研究*

doi:10.3969/j.issn.1672-5069.2020.02.026

Abstract

Abstract: Objective The aim of this study was to investigate the clinical value of echocardiography in evaluating cardiac structure and function in patients with liver cirrhosis (LC). Methods A total of 124 patients with liver cirrhosis and 60 healthy persons were recruited in this study between April, 2018 and April, 2019, and all underwent echocardiography. The model for end-stage liver disease (MELD) were calculated in patients with LC, and 41 were found to be mild with MELD score of ≤9, 35 moderate with 10≤MELD score ≤19, and 22 severe with MELD score ≥20. The cardiac parameters measured by echocardiography included left-atrial end-systolic diameter (LAs), left-ventricular end-diastolic diameter (LVd), right-atrial end-systolic diameter (RAs), right-ventricular end-diastolic diameter (RVd), left-ventricular ejection fraction (LVEF), and Ea/Aa ratio of mitral annulus by tissue Doppler imaging (TDI) mode, and the pulmonary artery systolic pressure (PASP) in cirrhotic patients was estimated. Results The LAs in the control group and in the cirrhosis group were (36.3±3.1) and (37.8±4.3), respectively, LVd were (47.8±2.8) and (49.4±4.6), respectively, and the Ea/Aa ratio were (1.1±0.3) and (1.0 ±0.2), respectively, all significantly different (P <0.05); In the mild, moderate, and severe groups of patients with liver cirrhosis, LAs were (36.1±4.2), (38.2±4.1), and (40.1±3.7), respectively, LVd were (47.4±4.5), (50.3±4.4) and (51.4±3.8), respectively, and PASP were (31.2±4.6), (33.4±4.5) and (35.1±5.4), respectively, all significantly different (P <0.05); out of the 124 patients with liver cirrhosis, 9 cases (7.3%) had PASP>40mmHg, diagnosed as having pulmonary hypertension (PAH) . Conclusion With the progression of end-stage liver disease, the function of the hearts in patients with liver cirrhosis gradually decrease, and echocardiography has the clinical application value with high sensitivity and repeatability in evaluating cardiac function and estimating pulmonary artery pressure in cirrhotic patients.

Key words: Liver cirrhosis, Echocardiography, Cardiac function, Pulmonary hypertension

Hu Xing, Meng Fankun, Han Jing, et al. Clinical value of echocardiography in evaluating cardiac structure and function in patients with liver cirrhosis[J]. Journal of Practical Hepatology, 2020, 23(2): 252-255.

References

[1] Ruiz-del-Arbol L, Serradilla R. Cirrhotic cardiomyopathy. World J Gastroenterol, 2015, 21(41):11502-11521.
[2] Liu H, Jayakumar S, Traboulsi M, et al. Cirrhotic cardiomyopathy: implications for liver transplantation. Liver Transpl, 2017,23(6):826-835.
[3] Hachulla AL, Rautou PE, Franchi-Abella S, et al. Impact of liver diseases on heart and lungs. JACC Cardiovasc Imaging,2019, 38(2): 150-157.
[4] Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American association for the study of liver diseases. Hepatology, 2017,65(1): 310-335.
[5] Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology, 2007, 45(3): 797-805.
[6] 苗俊旺, 尹立雪. 肝硬化性心肌病的超声心动图研究进展. 中华超声影像学杂志, 2013,22(3): 263-265.
[7] El-Kharashi OA, Mohamed DI, Khairy E, et al. Exenatide promotes cardiac lncRNAshoxtranscript antisense RNA (hotair) in wistar rats with liver cirrhosis: a novel role of GLP-1 receptor agonists in cirrhotic cardiomyopathy. Eur J Pharmacol, 2019, 855(7): 294-304.
[8] Moon DB, Lee SG, Kang WH, et al. Adult living donor liver transplantation for acute-on-chronic liver failure in high-model for end-stage liver disease score patients. Am J Transplant 2017,17(7): 1833-1842.
[9] Azevedo PS, Polegato BF, Minicucci MF, et al. Cardiac remodeling: concepts, clinical impact,pathophysiological mechanisms and pharmacologic treatment. Arq Bras Cardiol, 2016, 106(1): 62-69.
[10] Silvestre OM, Bacal F, de Souza Ramos D, et al. Impact of the severity of end-stage liver disease in cardiac structure and function. Ann Hepatol, 2013, 12(1): 85-91.
[11] Marconi C, Bellan M, Giarda P, et al. Cardiac dysfunction as an early predictor of portal hypertension in chronic hepatitis C. Ann Gastroenterol 2017,30(6): 675-681.
[12] Cesari M, Frigo AC, Tonon M, et al. Cardiovascular predictors of death in patients with cirrhosis. Hepatology, 2018, 68(1): 215-223.
[13] 简佑容, 陈世耀. 肝硬化门脉高压症患者心脏功能影响因素及其状况评价. 实用肝脏病杂志, 2018, 21(3): 336-339.
[14] 孙福荣, 孟一曼, 王炳元, 等. 终末期肝病患者终末期肝病模型评分与左心功能的关系. 中华肝脏病杂志, 2010, 18(10): 758-762.
[15] Moller S, Wiese S, Halgreen H, et al. Diastolic dysfunction in cirrhosis. Heart Fail Rev, 2016, 21(5): 599-610.
[16] Porres-Aguilar M, Altamirano JT, Torre-Delgadillo A, et al. Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview. Eur Respir Rev, 2012, 21(125): 223-233.
[17] 陈丹, 钟鸿斌, 林黛茜, 等. 超声心动图联合心电图对先天性心脏病相关性肺动脉高压的预测价值. 中华高血压杂志, 2017,25(8): 767-772.
[18] ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American college of cardiology foundation task force on expert consensus documents and the American heart association developed in collaboration with the American college of chest physicians, American thoracic society, Inc., and the pulmonary hypertension association. J Am Coll Cardiol, 2009,53(17): 1573-1619.
[19] Ripoll C, Catalina MV, Yotti R, et al. Cardiac dysfunction during liver transplantation: incidence and preoperative predictors. Transplantation, 2008, 85(12):1766-1772.
[20] Zardi EM, Zardi DM, Chin D, et al. Cirrhotic cardiomyopathy in the pre- and post-liver transplantation phase. J Cardiol, 2016, 67(2):125-130.

Clinical value of echocardiography in evaluating cardiac structure and function in patients with liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Huiyong, Wu Xiuxin, Xu Chengrun. Clinical efficacy of ultrafiltration, concentration and reinfusion of ascites and alprostadil and terlipressin combination in treatment of patients with cirrhosis complicated by refractory ascites [J]. Journal of Practical Hepatology, 2020, 23(2): 244-247.
[2]	A Sigen, Xia Yijun, Wu Huijun, et al. Efficacy of laparoscopic portal-azygos vein devascularization and splenectomy in treatment of patients with cirrhotic portal hypertension [J]. Journal of Practical Hepatology, 2020, 23(2): 248-251.
[3]	Xing Lekang, Deng Yongdong, Yao Liqiong, et al. Changes of intestinal flora in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(2): 256-259.
[4]	Xu Xiaoyuan. Highlights of newly released guideline for diagnosis and treatment of liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(1): 4-6.
[5]	Zhou Xiaoxu, Zhang Huajie. Evaluation of fetal cardiac functions by velocity vector imaging in pregnant women with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2020, 23(1): 62-65.
[6]	Yang Xiaoling, Zhang Sumei. Application of SGA, MNA and NRS2002 in nutritional assessment of patients withdecompensated liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(1): 70-73.
[7]	Wang Jingjing, Li Chuntao, Zhou Weizhen. Urineretinol binding protein levels in patients with hepatitis B-induced decompensated liver cirrhosis as the index for acute kidney injury [J]. Journal of Practical Hepatology, 2020, 23(1): 74-77.
[8]	Yang Huiling, Liu Xiaojing, He Yingli, et al. Clinical characteristicsof and risk factors for nosocomial infections in patients with hospitalized decompensated hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(1): 78-81.
[9]	Zhao Ping, Li Tao, Xie Jiliang, et al. Value of early anticoagulant intervention in cirrhotic patients with portal hypertension after transjugular intrahepatic portosystemic stent shunt combined with PSE [J]. Journal of Practical Hepatology, 2020, 23(1): 82-85.
[10]	Zhang Bing, Xie Xuejun. Correlation of polymorphisms of CTLA-4 and PNPLA3 genes tothe pathogenesis of alcoholic cirrhosis in human [J]. Journal of Practical Hepatology, 2020, 23(1): 86-89.
[11]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[12]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[13]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[14]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[15]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.